LEGEND BIOTECH CORPORATION |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 45.3 USD | +1.98% |
|
-1.93% | -24.71% |
| 04-23 | Genscript Biotech Unit Gets Approval for Blood Cancer Drug by European Commission | MT |
| 04-22 | Legend Biotech's Carvykti Gets European Commission Approval for Treatment of Blood Cancer | MT |
| Sales 2024 * | 585M 799M | Sales 2025 * | 1.08B 1.47B | Capitalization | 8.24B 11.25B |
|---|---|---|---|---|---|
| Net income 2024 * | -316M -432M | Net income 2025 * | -92M -126M | EV / Sales 2024 * | 12.5 x |
| Net cash position 2024 * | 928M 1.27B | Net cash position 2025 * | 835M 1.14B | EV / Sales 2025 * | 6.88 x |
| P/E ratio 2024 * |
-41.9
x | P/E ratio 2025 * |
-141
x | Employees | 1,800 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 99% |
More Fundamentals
* Assessed data
More news
Latest transcript on Legend Biotech Corporation
More recommendations
More press releases
More news
| 1 day | +1.98% | ||
| 1 week | -1.93% | ||
| Current month | -19.24% | ||
| 1 month | -20.43% | ||
| 3 months | -19.89% | ||
| 6 months | -28.85% | ||
| Current year | -24.71% |
1 week
44.06
48.55
1 month
44.0657.64
Current year
44.0670.13
1 year
44.0677.32
3 years
27.7177.32
5 years
23.4177.32
10 years
23.4177.32
| Managers | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Lori Macomber
DFI | Director of Finance/CFO | 53 | 19-08-31 |
Tracy Luo
CTO | Chief Tech/Sci/R&D Officer | - | 18-04-30 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Ying Huang
CEO | Chief Executive Officer | 51 | 19-06-30 |
Corazon Sanders
BRD | Director/Board Member | 67 | 20-04-30 |
Li Zhu
BRD | Director/Board Member | 74 | 20-11-22 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 3.08% | 4 M€ | -27.92% | ||
| 1.18% | 2 M€ | -14.14% | ||
| 0.99% | 2 M€ | -16.59% | - | |
| 0.95% | 11 M€ | -6.03% | - | |
| 0.58% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-26 | 45.3 | +1.98% | 895,893 |
| 24-04-25 | 44.42 | -1.66% | 1,849,777 |
| 24-04-24 | 45.17 | -4.81% | 1,089,079 |
| 24-04-23 | 47.45 | +0.83% | 1,813,170 |
| 24-04-22 | 47.06 | +1.88% | 756,637 |
Delayed Quote Nasdaq, April 26, 2024 at 04:00 pm
More quotes
Legend Biotech Corporation is a clinical-stage biopharmaceutical company. The Company is engaged in the discovery and development of cell therapies for oncology and other indications. Its lead product candidate, ciltacabtagene autoleucel (cilta-cel), referred to as LCAR- B38M, is an autologous chimeric antigen receptor (CAR-T) cell therapy that targets the B-cell maturation antigen (BCMA), which is a highly expressed protein in several hematologic malignancies, including multiple myeloma (MM). In addition to cilta-cel, the Company has a portfolio of earlier-stage autologous CAR-T product candidates targeting various cancers, including Non-Hodgkins Lymphoma, acute lymphoblastic leukemia, gastric cancer, esophageal cancer, pancreatic cancer, colorectal cancer, hepatocellular carcinoma, small cell lung cancer, and non-small cell lung cancer. It is also engaged in developing an allogeneic gamma delta CAR-T product candidate and an allogeneic CAR-NK product candidate targeting BCMA for MM.
Calendar
2024-05-12
- Q1 2024 Earnings Release
Trading Rating
Investor Rating
ESG Refinitiv
D
Sell
Buy
Mean consensus
BUY
Number of Analysts
21
Last Close Price
45.3
USD
Average target price
86.33
USD
Spread / Average Target
+90.57%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -24.71% | 8.24B | |
| -2.31% | 103B | |
| +0.56% | 95.28B | |
| +1.69% | 22.15B | |
| -17.37% | 21.02B | |
| -9.30% | 18.15B | |
| -41.01% | 16.73B | |
| -14.85% | 16.05B | |
| +3.21% | 13.68B | |
| +33.54% | 12.17B |
- Stock Market
- Equities
- LEGN Stock
